New hope for tough lung cancer: targeted pill takes on Chemo-Resistant tumors
NCT ID NCT05450965
First seen Jan 05, 2026 · Last updated Jun 03, 2026 · Updated 19 times
Summary
This study tests a drug called onvansertib in about 37 adults with small cell lung cancer that came back or didn't respond to chemo. Onvansertib blocks a protein (PLK1) that cancer cells need to repair themselves, aiming to shrink tumors. The main goal is to see how many patients have their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
ACTIVE_NOT_RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
University of Maryland Greenebaum Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21201, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.